Pharmacogenetic aspects of the dopaminergic system in clozapine pharmacodynamics

Kravtsov, Vadim; Filippov, I.A.; Vaiman, Elena E.; Shnayder, N. А.; Насырова, Р. Ф.

doi:10.17116/jnevro2020120071134

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the generation of new APs, the problem of AP-induced adverse drug reactions (ADRs) has not been solved yet, and the accumulated experience in targeted prevention of AP-induced ADRs suggests that most of them can be prevented or their consequences can be significantly reduced [2,3].…”

Section: Introductionmentioning

confidence: 99%

“…); -non-modifiable factors (gender, age of patients, genetic predisposition). The study of genetic predisposition to the development of AP-induced ADRs is based on associative genetic studies and genome-wide studies of single nucleotide variants (SNVs) and polymorphisms of the candidate genes involved in the metabolism, transport, cumulation, excretion of APs and their active metabolites [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Case of a 36-Year-Old Man with Treatment-Resistant Paranoid Schizophrenia: Personalized Therapy Selection

Linova

Torgovtsev

Лиманкин

et al. 2022

jour

View full text Add to dashboard Cite

Schizophrenia is a common and socially significant mental disorder that requires longterm use of antipsychotics (APs). Long-term use of APs increases the risk of developing adverse drug reactions (ADRs) and/or therapeutic resistance in some patients. This may be due to a genetically determined impairment of APs metabolism by cytochrome P450 enzymes and of Aps transport across the blood-brain barrier (BBB) and the cell membrane of APs target neurons in the brain. Pharmacogenetic testing (PGx) is a method to identify a group of patients with a high risk of developing AP-induced ADRs. The aim of the case report is to present the experience of using PGx in a 36-year-old patient with treatment-resistant schizophrenia and a medical history of AP-induced ADRs.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical Case of a 36-Year-Old Man with Treatment-Resistant Paranoid Schizophrenia: Personalized Therapy Selection

Linova

Torgovtsev

Лиманкин

et al. 2022

jour

View full text Add to dashboard Cite

show abstract

Evidence of Pharmacogenetics-Based Fluvoxamine Use as an Add-On to Clozapine Treatment in Psychiatry

et al. 2022

View full text Add to dashboard Cite

Pharmacological treatments used for psychiatric disorders, such as clozapine, demonstrate large interindividual variability in terms of possible adverse effects and therapeutic benefit. This variability can be explained by multiple factors, including pharmacogenetic factors. Clozapine efficacy can be impacted by CYP polymorphisms. A growing body of literature on pharmacogenetics suggests the clinical benefit of concomitant use of clozapine and fluvoxamine to improve global pharmacotherapeutic management. This article reviews and discusses available clinical and pharmacological data and limitations of clozapine augmentation with fluvoxamine based on pharmacogenetic rationale and clinical experience. The aim is to provide an updated approach on how to use the pharmacological and pharmacogenetic profile to improve clozapine efficacy and tolerance in severely ill patients.

show abstract

Pharmacogenetic Testing of Cytochrome P450 Metabolizing Enzymes in 28-Year-Old Man with Treatment-Resistant Schizophrenia

Abdyrakhmanova

Насырова

2022

jour

View full text Add to dashboard Cite

Schizophrenia is a common and socially significant mental disorder that requires longterm use of antipsychotics (APs). Long-term use of APs increases the risk of developing adverse drug reactions (ADRs) and/or therapeutic resistance in some patients. This may be due to a genetically determined impairment of APs metabolism by cytochrome P450 enzymes. Pharmacogenetic testing (PGx) is a method to identify a group of patients with a high risk of developing AP-induced ADRs. Our experience of using PGx to search for low-functional and non-functional single nucleotide variants (SNVs) / polymorphisms of the CYP1A2, CYP2C9, CYP3A4, CYP3A5 and CYP2D6) genes encoding cytochrome P450 enzymes involved in APs metabolism demonstrates the importance of this new personalized approach to the choice of APs and its dosing in patients with pharmacogenetic profile poor metabolizer. The main purpose of the case report is to present the experience of using PGx in a 28-year-old patient with treatment-resistant schizophrenia and a medical history of AP-induced ADRs.

show abstract

Pharmacogenetic aspects of the dopaminergic system in clozapine pharmacodynamics

Cited by 3 publications

References 35 publications

Clinical Case of a 36-Year-Old Man with Treatment-Resistant Paranoid Schizophrenia: Personalized Therapy Selection

Clinical Case of a 36-Year-Old Man with Treatment-Resistant Paranoid Schizophrenia: Personalized Therapy Selection

Evidence of Pharmacogenetics-Based Fluvoxamine Use as an Add-On to Clozapine Treatment in Psychiatry

Pharmacogenetic Testing of Cytochrome P450 Metabolizing Enzymes in 28-Year-Old Man with Treatment-Resistant Schizophrenia

Contact Info

Product

Resources

About